Volume 5, Issue 1 (2026) – 10 articles
Cover Picture: This review summarizes the shift in systemic lupus erythematosus (SLE) treatment from glucocorticoid-based therapy to mechanism-driven, targeted, and increasingly personalized approaches. It highlights that past clinical trial failures are largely due to disease heterogeneity and suboptimal trial design.
The field is now rapidly advancing, with over 300 ongoing or planned interventional studies and multiple promising targeted agents in late-stage development. Overall, SLE therapy is entering a new era of precision medicine, although challenges in patient stratification and clinical translation remain.
view this paper The field is now rapidly advancing, with over 300 ongoing or planned interventional studies and multiple promising targeted agents in late-stage development. Overall, SLE therapy is entering a new era of precision medicine, although challenges in patient stratification and clinical translation remain.
